Abstract
Compositions comprising at least one of miR that down regulates PD-L1/PD-1, MSCs expressing same, or exosomes from those MSCs are provided. Methods of decreasing PD-L1 expression, PD-1 expression or both and treating PD-L1 positive cancers using same are also provided.
| Original language | English |
|---|---|
| Patent number | US20210260141A1 |
| State | Published - 26 Aug 2021 |
Bibliographical note
US Patent App. 17/261,078UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Msc-and exosome-based immunotherapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver